Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Pancreatic Cancer
- Sponsor
- Zhejiang Provincial People's Hospital
- Enrollment
- 7
- Locations
- 1
- Primary Endpoint
- Number of participants experiencing clinical and laboratory adverse events (AEs)
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This research study is evaluating a new type of pancreatic cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for advanced pancreatic cancer. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of Chinese patients with advanced pancreatic cancer, so as to provide a new personalized therapeutic strategy for advanced pancreatic cancer patients.
It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.
Investigators
Liu Yang
MD
Zhejiang Provincial People's Hospital
Eligibility Criteria
Inclusion Criteria
- •Must freely sign informed consent;
- •Aged 18 to 70 years old;
- •The expected survival period is more than 6 months;
- •ECOG score is 0 or 1;
- •Advanced pancreatic cancer diagnosed by Pathology and imageology;
- •Tumor cannot be excised by surgery, and multiline chemotherapy, radiation, targeted therapy fails, or other treatments cannot be tolerated;
- •At least one measurable lesions;
- •To be able to obtain sufficient tumor tissue samples and blood samples for analysis, or to have genomic/exon/transcriptional data of tumor tissues and normal tissues, and the data meet the analysis requirements;
- •The main organs function is normal, such as the heart, liver and kidney;
- •Haematological index:
Exclusion Criteria
- •Diagnosed as other malignant tumor;
- •There have been bone marrow or stem cell transplants;
- •No neoantigen was found in the sequencing data;
- •Systemic cancer treatment or other drugs under study were treated within 4 weeks prior to Individualized tumor targeted polypeptides treatment;
- •Received other polypeptide inoculation 4 weeks before treatment; Patients may not be vaccinated with other polypeptides 8 weeks after the last individualized tumor targeted polypeptides trentment;
- •Active bacterial or fungal infections identified clinically (\>= level 2 of NCI-CTC edition 3);
- •Patients with HIV, HCV, HBV infection, severe asthma, autoimmune disease, immunodeficiency or treated with immunosuppressive drugs;
- •Severe coronary or cerebrovascular disease, or other diseases that the investigators considered should to be exclusion;
- •Drug abuse. Clinical, psychological or social factor result in affecting informed consent or research implementation;
- •Have a history of drug or polypeptide allergies, or people who are allergic to other potential immunotherapies.
Outcomes
Primary Outcomes
Number of participants experiencing clinical and laboratory adverse events (AEs)
Time Frame: 1 year
Objective Response Rate
Time Frame: 2 years
Secondary Outcomes
- Progression Free Survival(2 years)
- Overall Survival Rate(2 years)